21 March 2013
George Freeman highlights the importance of the Government’s life science strategy as pharmaceutical giant AstraZeneca’s decision to move its global R and D to Cambridge demonstrates.
George Freeman (Mid Norfolk) (Con): This week, AstraZeneca announced a deep global restructuring, committing its manufacturing facility to Cheshire, but moving its global R and D to Cambridge, with a £300 million investment and 2,000 staff. Does my right hon. Friend agree that that is a sharp reminder of the deep global restructuring in the pharmaceutical sector and the importance of the life science strategy we put in place 18 months ago? May I congratulate his Department on the speed with which the task force was set up?
Mr Willetts: The announcement was obviously disappointing for people at Alderley Park, but we have worked with AstraZeneca in setting up a task force, which I hope will secure a future for the site. Meanwhile, we should celebrate the fact that AstraZeneca decided, having looked around the world, that the UK was the best place to invest in new R and D facilities.
| Hansard
George Freeman (Mid Norfolk) (Con): This week, AstraZeneca announced a deep global restructuring, committing its manufacturing facility to Cheshire, but moving its global R and D to Cambridge, with a £300 million investment and 2,000 staff. Does my right hon. Friend agree that that is a sharp reminder of the deep global restructuring in the pharmaceutical sector and the importance of the life science strategy we put in place 18 months ago? May I congratulate his Department on the speed with which the task force was set up?
Mr Willetts: The announcement was obviously disappointing for people at Alderley Park, but we have worked with AstraZeneca in setting up a task force, which I hope will secure a future for the site. Meanwhile, we should celebrate the fact that AstraZeneca decided, having looked around the world, that the UK was the best place to invest in new R and D facilities.
| Hansard
